

Torsten Falk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9574628/publications.pdf>

Version: 2024-02-01

34
papers

783
citations

430442

18
h-index

525886

27
g-index

39
all docs

39
docs citations

39
times ranked

1078
citing authors

#	ARTICLE	IF	CITATIONS
1	Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2009, 4, 49.	4.4	56
2	A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 369, 9-25.	1.3	47
3	The Yin and Yang of VEGF and PEDF: Multifaceted Neurotrophic Factors and Their Potential in the Treatment of Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2010, 11, 2875-2900.	1.8	46
4	Neurochemical and electrophysiological characteristics of rat striatal neurons in primary culture. <i>Journal of Comparative Neurology</i> , 2006, 494, 275-289.	0.9	44
5	Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease. <i>Neuroscience</i> , 2014, 258, 385-400.	1.1	44
6	Pigment epithelium derived factor (PEDF) is neuroprotective in two in vitro models of Parkinson's disease. <i>Neuroscience Letters</i> , 2009, 458, 49-52.	1.0	41
7	Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease. <i>Neuroscience Letters</i> , 2011, 496, 43-47.	1.0	40
8	Retinal pigment epithelial cell transplantation could provide trophic support in Parkinson's disease: Results from an in vitro model system. <i>Experimental Neurology</i> , 2006, 201, 234-243.	2.0	39
9	Cloning, functional expression and mRNA distribution of an inwardly rectifying potassium channel protein. <i>FEBS Letters</i> , 1995, 367, 127-131.	1.3	38
10	PEDF and VEGF-A Output from Human Retinal Pigment Epithelial Cells Grown on Novel Microcarriers. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-8.	3.0	33
11	Can quantifying morphology and TMEM119 expression distinguish between microglia and infiltrating macrophages after ischemic stroke and reperfusion in male and female mice?. <i>Journal of Neuroinflammation</i> , 2021, 18, 58.	3.1	29
12	Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing L-DOPA-Induced Dyskinesias. <i>Case Reports in Neurology</i> , 2016, 8, 53-58.	0.3	28
13	Long-term effect of sub-anesthetic ketamine in reducing L-DOPA-induced dyskinesias in a preclinical model. <i>Neuroscience Letters</i> , 2016, 612, 121-125.	1.0	26
14	Insights into the Mechanisms Involved in Protective Effects of VEGF-B in Dopaminergic Neurons. <i>Parkinson's Disease</i> , 2017, 2017, 1-13.	0.6	26
15	Ten-Hour Exposure to Low-Dose Ketamine Enhances Corticostriatal Cross-Frequency Coupling and Hippocampal Broad-Band Gamma Oscillations. <i>Frontiers in Neural Circuits</i> , 2018, 12, 61.	1.4	25
16	Expression of Niemann-Pick type C transcript in rodent cerebellum in vivo and in vitro. <i>Brain Research</i> , 1999, 839, 49-57.	1.1	24
17	CNS penetration of the opioid glycopeptide MMP-2200: A microdialysis study. <i>Neuroscience Letters</i> , 2012, 531, 99-103.	1.0	23
18	Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia. <i>Experimental Neurology</i> , 2020, 333, 113413.	2.0	23

#	ARTICLE	IF	CITATIONS
19	An endogenous inactivating inward-rectifying potassium current in oocytes of <i>Xenopus laevis</i> . <i>Pflugers Archiv European Journal of Physiology</i> , 1996, 432, 812-820.	1.3	19
20	Effects of the novel glycopeptide opioid agonist MMP-2200 in preclinical models of Parkinson's disease. <i>Brain Research</i> , 2011, 1413, 72-83.	1.1	15
21	Over-expression of the potassium channel Kir2.3 using the dopamine-1 receptor promoter selectively inhibits striatal neurons. <i>Neuroscience</i> , 2008, 155, 114-127.	1.1	14
22	Differential expression of three classes of voltage-gated Ca ²⁺ channels during maturation of the rat cerebellum in vitro. <i>Developmental Brain Research</i> , 1999, 115, 161-170.	2.1	13
23	Viral vector-mediated expression of K ⁺ channels regulates electrical excitability in skeletal muscle. <i>Gene Therapy</i> , 2001, 8, 1372-1379.	2.3	13
24	The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced L-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia. <i>Neuropharmacology</i> , 2018, 141, 260-271.	2.0	13
25	Highly-selective μ -opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model. <i>BMC Research Notes</i> , 2020, 13, 149.	0.6	12
26	Differential effects of the NMDA receptor antagonist MK-801 on dopamine receptor D1- and D2-induced abnormal involuntary movements in a preclinical model. <i>Neuroscience Letters</i> , 2014, 564, 48-52.	1.0	11
27	Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine. <i>Experimental Neurology</i> , 2021, 340, 113670.	2.0	11
28	The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 20.	1.8	11
29	Design and Synthesis of Brain Penetrant Glycopeptide Analogues of PACAP With Neuroprotective Potential for Traumatic Brain Injury and Parkinsonism. <i>Frontiers in Drug Discovery</i> , 2022, 1, .	1.1	8
30	Sleep Spindles and Fragmented Sleep as Prodromal Markers in a Preclinical Model of LRRK2-G2019S Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 324.	1.1	7
31	Evaluation of microglia in a rodent model of Parkinson's disease primed with L-DOPA after sub-anesthetic ketamine treatment. <i>Neuroscience Letters</i> , 2021, 765, 136251.	1.0	1
32	Development of a Parkinson's disease model in medaka fish. <i>FASEB Journal</i> , 2012, 26, 998.1.	0.2	1
33	Evaluation of a Parkinson's disease model in medaka fish. <i>FASEB Journal</i> , 2013, 27, 567.1.	0.2	1
34	A herpes simplex viral vector expressing green fluorescent protein can be used to visualize morphological changes in high-density neuronal culture. <i>Electronic Journal of Biotechnology</i> , 2001, 4, 20-21.	1.2	1